WS #15255
Pfizer is submitting Phase 3 data for Litfulo (ritlecitinib) to the FDA and EMA, showing significant improvement in facial repigmentation for vitiligo patients. In the obesity space, Eli Lilly and Novo Nordisk are expanding their pipelines beyond GLP-1s by developing amylin-based drugs, aiming to offer new biological mechanisms for weight loss and metabolic health. These developments highlight continued innovation in niche therapeutic areas.
Pharma & Biotech Pipeline Updates
Pfizer is submitting Phase 3 data for Litfulo (ritlecitinib) to the FDA and EMA, showing significant improvement in facial repigmentation for vitiligo patients. In the obesity space, Eli Lilly and Novo Nordisk are expanding their pipelines beyond GLP-1s by developing amylin-based drugs, aiming to offer new biological mechanisms for weight loss and metabolic health. These developments highlight continued innovation in niche therapeutic areas.